Please use this identifier to cite or link to this item: https://doi.org/10.18632/oncotarget.3622
DC FieldValue
dc.titleNimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model
dc.contributor.authorBhuvaneswari, R
dc.contributor.authorNg, Q.F
dc.contributor.authorThong, P.S.P
dc.contributor.authorSoo, K.-C
dc.date.accessioned2020-09-10T02:01:49Z
dc.date.available2020-09-10T02:01:49Z
dc.date.issued2015
dc.identifier.citationBhuvaneswari, R, Ng, Q.F, Thong, P.S.P, Soo, K.-C (2015). Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model. Oncotarget 6 (15) : 13487-13505. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.3622
dc.identifier.issn19492553
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/175527
dc.description.abstractOral squamous cell carcinoma (OSCC) represents 90% of all oral cancers and is characterized with poor prognosis and low survival rate. Epidermal growth factor receptor (EGFR) is highly expressed in oral cancer and is a target for cancer therapy and prevention. In this present work, we evaluate the efficacy of photodynamic therapy (PDT) in combination with an EGFR inhibitor, nimotuzumab in oral cancer cell lines and OSCC xenograft tumor model. PDT is a promising and minimally invasive treatment modality that involves the interaction of a photosensitizer, molecular oxygen and light to destroy tumors. We demonstrated that EGFR inhibitors nimotuzumab and cetuximab exhibits anti-angiogenic properties by inhibiting the migration and invasion of oral cancer cell lines and human endothelial cells. The EGFR inhibitors also significantly reduced tube formation of endothelial cells. Chlorin e6-PDT in combination with nimotuzumab and cetuximab reduced cell proliferation in different oral cancer and endothelial cells. Furthermore, our in vivo studies showed that the combination therapy of PDT and nimotuzumab synergistically delayed tumor growth when compared with control and PDT treated tumors. Downregulation of EGFR, Ki-67 and CD31 was observed in the tumors treated with combination therapy. Analysis of the liver and kidney function markers showed no treatment related toxicity. In conclusion, PDT outcome of oral cancer can be improved when combined with EGFR inhibitor nimotuzumab.
dc.publisherImpact Journals LLC
dc.sourceUnpaywall 20200831
dc.subjectCD31 antigen
dc.subjectcetuximab
dc.subjectchlorin e6
dc.subjectepidermal growth factor receptor
dc.subjectKi 67 antigen
dc.subjectnimotuzumab
dc.subjectphotosensitizing agent
dc.subjectunclassified drug
dc.subjectEGFR protein, human
dc.subjectepidermal growth factor receptor
dc.subjectmonoclonal antibody
dc.subjectnimotuzumab
dc.subjectphytochlorin
dc.subjectporphyrin
dc.subjectradiosensitizing agent
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectantiangiogenic activity
dc.subjectantineoplastic activity
dc.subjectantiproliferative activity
dc.subjectapoptosis
dc.subjectArticle
dc.subjectcancer inhibition
dc.subjectcancer size
dc.subjectcell invasion
dc.subjectchemotaxis
dc.subjectconcentration response
dc.subjectcontrolled study
dc.subjectdown regulation
dc.subjectdrug potentiation
dc.subjectdrug safety
dc.subjectendothelium cell
dc.subjectextracellular matrix
dc.subjectHSC 3 cell line
dc.subjecthuman
dc.subjecthuman cell
dc.subjectimmunohistochemistry
dc.subjectkidney function
dc.subjectlight exposure
dc.subjectliver function
dc.subjectmigration inhibition
dc.subjectmouth squamous cell carcinoma
dc.subjectnonhuman
dc.subjectoral cancer cell line
dc.subjectphotodynamic therapy
dc.subjectSCC 25 cell line
dc.subjecttherapy effect
dc.subjecttreatment response
dc.subjecttumor xenograft
dc.subjectumbilical vein endothelial cell
dc.subjectanimal
dc.subjectantagonists and inhibitors
dc.subjectBagg albino mouse
dc.subjectbiosynthesis
dc.subjectCarcinoma, Squamous Cell
dc.subjectcell proliferation
dc.subjectdrug effects
dc.subjectdrug screening
dc.subjectenzymology
dc.subjectHead and Neck Neoplasms
dc.subjectmouse
dc.subjectMouth Neoplasms
dc.subjectmultimodality cancer therapy
dc.subjectnude mouse
dc.subjectpathology
dc.subjectphotochemotherapy
dc.subjectprocedures
dc.subjectrandomization
dc.subjecttumor cell line
dc.subjectAnimals
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectCarcinoma, Squamous Cell
dc.subjectCell Line, Tumor
dc.subjectCell Proliferation
dc.subjectCombined Modality Therapy
dc.subjectDrug Synergism
dc.subjectHead and Neck Neoplasms
dc.subjectHuman Umbilical Vein Endothelial Cells
dc.subjectHumans
dc.subjectMice
dc.subjectMice, Inbred BALB C
dc.subjectMice, Nude
dc.subjectMouth Neoplasms
dc.subjectPhotochemotherapy
dc.subjectPorphyrins
dc.subjectRadiation-Sensitizing Agents
dc.subjectRandom Allocation
dc.subjectReceptor, Epidermal Growth Factor
dc.subjectXenograft Model Antitumor Assays
dc.typeArticle
dc.contributor.departmentDEPT OF PHYSICS
dc.contributor.departmentDEPT OF SURGERY
dc.description.doi10.18632/oncotarget.3622
dc.description.sourcetitleOncotarget
dc.description.volume6
dc.description.issue15
dc.description.page13487-13505
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_18632_oncotarget_3622.pdf9.08 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

11
checked on Nov 27, 2020

Page view(s)

19
checked on Nov 27, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.